OTCMKTS:MDNAF Medicenna Therapeutics Q4 2026 Earnings Report $0.31 0.00 (0.00%) As of 09/18/2026 03:54 PM Eastern ProfileEarnings HistoryForecast Medicenna Therapeutics EPS ResultsActual EPS-$0.05Consensus EPS -$0.05Beat/MissMet ExpectationsOne Year Ago EPSN/AMedicenna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicenna Therapeutics Announcement DetailsQuarterQ4 2026Date6/25/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Medicenna Therapeutics Earnings HeadlinesMedicenna to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3, 2026 | financialpost.comFMedicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming ConferencesAugust 14, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 21 at 1:00 AM | Stansberry Research (Ad)Medicenna Therapeutics Corp. GAAP EPS of -C$0.22June 26, 2026 | seekingalpha.comMedicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational HighlightsJune 26, 2026 | globenewswire.comMedicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine PlatformsJune 11, 2026 | financialpost.comFSee More Medicenna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicenna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicenna Therapeutics and other key companies, straight to your email. Email Address About Medicenna TherapeuticsMedicenna Therapeutics (OTCMKTS:MDNAF) is a Canadian clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company uses its proprietary Superkine platform to engineer cytokine-based medicines designed to stimulate or direct immune responses against tumors while potentially reducing some of the limitations associated with naturally occurring cytokines. Its lead program, MDNA11, is an engineered interleukin-2 (IL-2) super-agonist intended to activate cancer-fighting immune cells and is being evaluated in clinical studies for advanced solid tumors. Medicenna has also developed MDNA55, an IL-4–targeted fusion protein designed to deliver a cell-killing payload to tumors that express the interleukin-4 receptor, including recurrent glioblastoma. The company’s development activities have included clinical research in North America and collaborations with academic and clinical institutions. Medicenna was founded in Canada and is headquartered in Toronto, Ontario. The company is led by Fahar Merchant, who serves as president and chief executive officer and is one of its founders. Medicenna’s shares trade in the United States under the symbol MDNAF.View Medicenna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to GrowthThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big Move Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
